AMRN Related Corporate News
-
Amarin (AMRN) Receives FDA Approval for BASF sNDA as Vascepa API
-
Amarin (AMRN) sNDA for Vascepa Accepted by U.S. FDA
-
Amarin (AMRN) Approved to Add Chemport as Additional Vascepa API Supplier
-
Amarin (AMRN) Vascepa Added to CVS (CVS) Health Plan
-
Amarin (AMRN) Issues Encouraging Update on Vascepa MARINE, ANCHOR Phase 3s
-
Amarin (AMRN) Vascepa NCE Not in Feb. Orange Book Update
-
Amarin (AMRN) Receives Additional Patent Allowance for Vascepa
-
Amarin Corp (AMRN) Files sNDA with U.S. FDA for Vascepa; Sees Response in 74 Days
-
Amarin (AMRN) Announces Patent Allowance Related to Vascapa
-
Amarin (AMRN) Receives NoA from USPTO on '146 App
-
Amarin (AMRN) Announces Patent Update for Vascepa
-
Amarin (AMRN) to Launch Vascepa in U.S. on Jan. 28th
-
Amarin (AMRN) Receives Notice of Allowance for Patent App '569
-
Amarin (AMRN) Publishes Additional Data for MARINE, ANCHOR Phase 3s
-
Amarin (AMRN) Receives U.S. Patent Allowance on '217 App for Vascepa MARINE Trial
-
Amarin (AMRN) Announces sNDA Submission for BASF as additional Vascepa Supplier
-
Humana Says Amarin's (AMRN) Vascepa Will Require Prior Authorization for Coverage
-
Amarin Corp (AMRN) Submits sNDA for New Vascepa API Supplier
-
Amarin (AMRN) Completes Vascepa Pharmacokinetic Sampling Study
-
Amarin (AMRN) Receives Notice of Allowance for '450 Patent
-
Amarin (AMRN) Announces Fourth Vascepa Supplier
-
Amarin (AMRN) Enters $100M Non-Equity Financing Agreement; Hiring for Vascepa Sales Launch
-
Amarin (AMRN) Issused Patent 8,324,195 for Vascepa
-
Amarin (AMRN) Delays Hiring Vascepa Sales Reps Until Early December
-
Amarin Corp (AMRN) Receives U.S. Patent Covering Vascepa
-
Amarin (AMRN) Announces Notification of Patent Allowance for U.S. Application
-
Amarin (AMRN) Receives U.S. Patent '4088 Covering Vascepa
-
Amarin (AMRN) Receives NoA from USPTO on '775 Patent
-
Amarin Corp Plc (AMRN) Posts Q3 adj.Loss of 26c/Share; Updates on Vascepa Approvals, Exclusivity
-
Amarin (AMRN) Granted Two Additional Patents for Vascepa
-
Amarin (AMRN) Says Vascepa Will Not Be in FDA's Sept. Orange Book
-
Amarin (AMRN) Gets USPTO Notice of Allowance for '150 App
-
Amarin (AMRN) Receives Notification of Patent Allowance for 13/284,408
-
Amarin Corp (AMRN) Gets USPTO Notice of Allowance for '889, '153 Apps
-
Amarin Corp. (AMRN) Receives USPTO Notice of Allowance for '145 App
-
Amarin (AMRN) Vascepa Met Primary Efficacy Endpoinst in Recent MARINE Phase 3
-
Amarin (AMRN) Wins FDA Approval of Vascepa
-
Amarin (AMRN) Gets Intention to Grant Patent in Europe for AMR101
-
Amarin Corp. (AMRN) Says Publication of ANCHOR Phase 3 Results Available
-
Amarin Corp. (AMRN) Gets Additional Notice of Allowance for U.S. Patent '885
-
Amarin (AMRN) to Present Data from Pivotal ANCHOR Phase 3 at ADA's 72nd Scientific Sessions
-
Amarin Corp. (AMRN) Gets U.S. Patent for AMR101
-
Amarin (AMRN) Shares Continue Higher as M&A Chatter Persists, Peer Provides Concerning Phase 3 Data
-
Amarin (AMRN) Shares Move Lower as USPTO Requires Restriction/Election for '569 Patent
-
USPTO Allows Amarin's (AMRN) '598 Application, Investors Cheer
-
Amarin (AMRN) Affirms Receiving Patent '598 for AMR101
-
Amarin (AMRN) Shares Pare Loss as Traders Sell First, Ask Questions Later
-
USPTO Revises Transaction History for Amarin's (AMRN) '598 Patent to 'Document Verification'
-
Amarin (AMRN) Shares Rally as USPTO Updates Transaction History for '598 Patent, Leerink Calls Co. 'Prime' Takeover Target
-
Shares of Amarin (AMRN) Plunge as USPTO Issues Non-Final Rejection for 13/284,408 Patent
Back to AMRN Stock Lookup
